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Transcatheter aortic valve implantation (TAVI) is the current therapy
of choice for elderly patients with severe aortic valve stenosis [1–7].
European valvular heart disease guidelines restrict TAVI to centers
with cardiac surgery on site (highly ranked, low evidence: class I,
level C) [8]. The deﬁnition of “cardiac surgery on site” is unclear. Does
it mean “established and institutionalized in-hospital cardiac
surgery”, or does it mean the procedure should be performed with
“a heart team including cardiologists and cardiac surgeons from
external established institutions”? This deﬁnition is critical because
health insurance companies refer to the postulate of “cardiac surgery
on site” to refuse TAVI-reimbursement in smaller hospitals. Thus, in
rural areasTAVI cannotbeprovided. Elderlypatients, andspeciﬁcally TAVI-
candidates, are often immobile and do reject being sent to the big city
centers. Furthermore, social integrationof thesepatients into theirhomely
environment may contribute to post-procedural success. Lastly, limited
capacity in the city heart centers in parallel to an increasing number of
elderly patients in the countryside may delay treatment of this life-
threatening disease.
Immenstadt is a small town settled in the Allgäu Alps, one of the
major German country side tourist attractions. Its 155-bed district
hospital belongs to Clinic-Association Kempten-Oberallgäu. The next
institutionalized cardiac surgery center is N100 km away. Kempten–
Oberallgäu, although being a major tourist area, belongs to the
remotest German areas concerning cardiac surgery healthcare.
66 consecutive TAVI-patients admitted to Immenstadt hospital
(November 2010 to November 2012) were included into this retro-
spective analysis (Table 1). A CoreValve device (Medtronic Inc.,
Minneapolis, NM, USA) measuring 26 mm, 29 mm and 31 mm in
diameter was used exclusively. Written informed consent was obtained
from every patient. Data were compared to the 2011–12 pilot European
TAVI Sentinel Registry [9]. Data analysis was approved by the Ethical
Committee of Ulm University (06.03.2013). Continuous variables
(Microsoft Excel 2000) are reported as mean ± SD. Comparative
statistics between our cohort and the European Registry of TAVI [9]
was not possible as, in spite of two (unanswered) email enquiries to the
corresponding author, Registry raw data were not provided. Thus, we
directly compared mean values (CoreValve to CoreValve, Table 2).
Cardiac surgery expertise, team-training and continuous stand-by
were provided by the Sana Heart Center Stuttgart (SHS). Diagnosis of
severe aortic valve stenosis was made according to ESC guidelines
[10]. Extracardiac arteriopathy was evaluated by computer tomogra-
phy. TAVI-patients were approved by the Heart Team (cardiologist,
cardiac surgeon, anesthesiologist, cardiotechnician, theater-nurse).
TAVI-procedures were performed in a hybrid operation room under
general anesthesia. Femoral artery was prepared by the surgeon, TAVI-
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Table 1
Patient characteristics.
Variable 2011–12 pilot European
Sentinel Registry of TAVI
(total n = 4571)
nb of observations; (%)
[nb of patients]
Cardiovascular Center
Oberallgäu–Kempten
(total n = 65)
nb of observations; %
[nb of patients]
Male/female 2291 (50.1)/2280 (49.9)
[4571]
28 (43.1)/37 (56.9)
[65]
Age (years) 81.4 ± 7.1 [4571] 83.6 ± 5.7 [65]
BMI (kg/m2) 26.6 ± 4.9 [4571] 26.0 ± 4.6 [65]
NYHA III or IV (76.9) [4571] 45 (69.2) [65]
AVA (cm2) 0.68 ± 0.26 [4571] 0.59 ± 0.15 [63a]
Diameter CoreValve
implanted (mm)
Ø26: (40.8) Ø26: 20 (30.8)
Ø29: (53.1) Ø29: 37 (56.9) [65]
Ø31: (no data available) Ø31: 8 (12.3)
General anesthesia
(transfemoral procedures)
(62.9) 65 (100.0) [65]
Diabetes mellitus 1259 (27.7) [4547] 12 (18.5) [65]
Hypertension 2709 (73.9) [3664] 54 (83.1) [65]
Current smoking 185 (4.2) [4357] 2 (3.1) [65]
Atrial ﬁbrillation 557 (20.1) [2773] 28 (43.1) [65]
COPD 981 (25.5) [3844] 15 (23.1) [65]
Dialysis 265 (6.9) [3821] 1 (1.5) [65]
Previous stroke 206 (12.1) [4282] 8 (12.3) [65]
Previous MI 769 (16.9) [4549] 5 (7.7) [65]
Previous cardiac surgery 824 (18.0) [4505] 9 (13.8) [65]
Previous PCI 463 (20.2) [2289] 24 (36.9) [65]
Previous PM 430 (11.7) [3676] 8 (12.3) [65]
Extracardiac arteriopathy 671 (24.8) [2707] 16 (24.6) [65]
Previous AVR 74 (3.4) [2141] 0 (0.0) [65]
LVEF b30%: 40 (5.7) Severely reduced:
8 (12.3)
30–50%: 191 (27.2) [701] Moderately reduced:
15 (23.1) [65]
N50%: 470 (67.0) Good: 42 (64.6)
Signiﬁcant CAD
(stenosis N 50%)
669 (20.0) [3,343] 31 (47.7) [65]
Signiﬁcant LM
(stenosis N 50%)
215 (6.7) [3,343] 0 (0.0) [65]
Logistic EuroSCORE 20.2 ± 13.3 [4,394] 21.6 ± 12.6 [65]
nb: number; BMI: body/mass index; NYHA: New York Heart Association Functional Class;
AVA: aortic valve area; AVR: aortic valve replacement; CAD: coronaryartery disease; COPD:
chronic obstructive pulmonary disease; MI: myocardial infarction; LM: left main coronary
artery; LVEF: left ventricular ejection fraction; PCI: percutaneous coronary intervention;
PM: pacemaker.
a Due to anatomical difﬁculties hindering accurate measurement of AVA two values are
missing.
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procedure (18 French-sheaths) was performed by the cardiologist.
Balloon valvuloplasty (balloon-size 2 mm b aortic annulus-size)
included “rapid pacing”. Valve delivery was performed as high as
possible to avoid severe aortic valve insufﬁciency. Left ventricular
diastolic pressure served as the major hemodynamic parameter to
decide on ﬁnal placement of the valve. Two procedures were live-
transmitted to Tongji University, Shanghai (http://www.prnewswire.-
co.uk/cgi/news/release?id = 333215). Immediately after the procedure,
patients were extubated and transferred to intensive care unit. The SHS-
Team left Immenstadt on the same day. Usually, temporary pacemaker
and central vein catheter could be removed within 24 h. Patients were
mobilized thenext dayand thenvisited twice a day until discharge. None
of the patients were transferred to another hospital.
Aortic insufﬁciency after TAVI was graded 0–III with ﬁrst
transthoracic echocardiography: 0 — no aortic valve insufﬁciency, I
— mild insufﬁciency, II — medium insufﬁciency, and III — severe
insufﬁciency. In case of intermediate grading (0–I, I–II or II–III), an
alternating ﬁnal assignment to lower or higher grade was used.
For direct comparison: in the pilot European Sentinel Registry [9], a
total of 4571 patients underwent TAVI in 137 centers of 10 European
countries. Average age was 81.4 ± 7.1 years (vs. 83.6 ± 5.68 in our
retrospective analysis). Logistic EuroSCORE was 20.2 ± 13.3 (vs.
21.6 ± 12.58 in our analysis). Access site was femoral approach in 74.2%
only (vs. 98.5% in our analysis — one patient was transferred to
transapical procedure at SHS).
In-hospital mortality in the Registry was 7.4% overall, 5.9% for
transfemoral (vs. 4.62% in our analysis) and 12.8% for transapical
approach. Surgical conversion rate was 5.5% (vs. 0.0% in our analysis).
Postprocedural pacemaker implantation was the most frequent com-
plication in our population with an incidence of ~20%. Less blood
transfusions (6.2% vs. 16.7%), less strokes (0% vs. 1.8%) and less major
vascular complications (1.5% vs. 2.8%) were seen in our population
compared with the Registry. The latter may be explained by routine
surgical preparation of femoral artery in our study. The only observed
vascular complicationwas an aneurysma spurium closedwith thrombin
injection after 3 days. In contrast, Registry patients received various
closing systemswhich are associatedwithmore bleeding complications
[9]. Postprocedural aortic regurgitation in our study was graded as
signiﬁcant in 18.1% (grade II— 15% and grade III — 3.1% of the patients)
vs.12.2% in the Registry. Higher grades of aortic insufﬁciencymay partly
be explained by our grading system. Also, retrospective analysis may be
more objective than prospective inclusion of quality data into a Registry
by the study center itself. Mean duration of in-hospital stay for TAVI-
procedure was 12.5 ± 5.9 days. This is longer compared to 9.3 ±
8.1 days in the Registry, but is in accordance with the German
Diagnosis Related Group (DRG)-based Healthcare-System (16.7 days
median in-hospital stay). Also, general anesthesia is associated with a
prolongation of in-hospital stay [9].
Our study has a number of limitations and conclusions. The number
of patients in our retrospective analysis is relatively low. Statistical
analysis comparing our data with the European Registry was not
permitted [see above]. Nonetheless, non-inferiority can be concluded:
mean age and logistic EuroSCOREwere higher, and in-hospitalmortality
was lower in our study population. Surgical access to the femoral artery
may be considered as standard access for TAVI. The deﬁnition of “cardiac
surgery on site” should be clariﬁed. Given that elderly patients are often
immobile and do not regularly reach the big city centers, TAVI should be
performed and reimbursed also in district hospitals provided that a
well-trained and professional Heart Team is involved.
• Clinic Association Kempten–Oberallgäu.
• German Chancellor Fellowship (Alexander von Humboldt Founda-
tion) to Dr. Kefei Li.
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Table 2
Procedural and in-hospital complications (CoreValve to CoreValve).
Variable 2011–12 pilot European
Sentinel Registry of TAVI
(total n = 1943)
nb of observations; (%)
Cardiovascular Center
Oberallgäu–Kempten
(total n = 65)
nb of observations; %
Unsuccessful valve delivery 67 (3.6) 1 (1.5) [n = 66]
Surgical conversion 106 (5.5) 0 (0.0)
Second valve implanted 60 (3.7) 2 (3.1)
Cardiac tamponade 37 (2.3) 3 (4.6)
Device embolization 10 (0.6) 2 (3.1)
Major vascular complications 20 (2.8) 1 (1.5)
Pacemaker implantation 321 (23.4) 12 (18.5)
Hemodialysis/ﬁltration 17 (1.1) 6 (9.2)
Need transfusion(s) 268 (16.7) 4 (6.2)
Stroke 33 (2.1) 0 (0.0)
In-hospital MI 20 (1.2) 1 (1.5)
New onset AF 74 (6.3) 0 (0.0)
Hospital stay N10 days 386 (25.1) 31 (47.7)
Aortic regurgitation grade 2 105 (9.9) 10 (15.0)
Aortic regurgitation grade 3 25 (2.3) 2 (3.1)
Death 131 (6.7) 3 (4.6)
nb: number; MI: myocardial infarction; AF: atrial ﬁbrillation.
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